Eli Lilly's tirzepatide showed efficacy in phase 3 trials for obstructive sleep apnea, reducing AHI compared to a placebo.

Eli Lilly's stock rose 0.54% as its molecule, tirzepatide, successfully met its primary endpoints in phase 3 clinical trials for treating obstructive sleep apnea (OSA). The drug significantly reduced the apnea-hypopnea index (AHI) compared to a placebo. This marks a potential first for pharmaceutical treatment of OSA's underlying disease, which affects 80 million adults in the US.

April 17, 2024
17 Articles